1-3 of 3
Reggie Ewesuedo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jennifer Kimberly Lue, Don A. Stevens, Michael E. Williams, Jason Westin, Reggie Ewesuedo, Alice McDonald, Sagar Agarwal, Patrick Henrick, Rachelle Perea, Jared Gollob
Journal: Blood
Blood (2022) 140 (Supplement 1): 12143–12144.
https://doi.org/10.1182/blood-2022-170151
Published: 2022
Journal Articles

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Michele Mayo, Yogesh Chutake, Rahul Karnik, Alice McDonald, Patricia S. Cho, Jessica Filiatrault, Dapeng Chen, Vaishali Dixit, William Proctor, Susanne Breitkopf, Frank Qi, Kan-Nian Hu, Kirti Sharma, Reggie Ewesuedo, Matt Weiss, Joseph D. Growney, Juliet Williams, Stefanie S Schalm
Journal: Blood
Blood (2022) 140 (Supplement 1): 6239–6240.
https://doi.org/10.1182/blood-2022-169021
Published: 2022
Journal Articles

A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Stephen D Smith, Alexander Starodub, Don A. Stevens, Aditi Shastri, Pierluigi Porcu, Tatyana Feldman, Reggie Ewesuedo, Chris DeSavi, Joyoti Dey, Sagar Agarwal, Sean Donohue, Rachelle Perea, Christine Klaus, Jared Gollob
Journal: Blood
Blood (2022) 140 (Supplement 1): 12024–12025.
https://doi.org/10.1182/blood-2022-169514
Published: 2022